» Articles » PMID: 23585686

Profile and Persistence of the Virus-specific Neutralizing Humoral Immune Response in Human Survivors of Sudan Ebolavirus (Gulu)

Overview
Journal J Infect Dis
Date 2013 Apr 16
PMID 23585686
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

To better understand humoral immunity following ebolavirus infection, a serological study of the humoral immune response against the individual viral proteins of Sudan ebolavirus (Gulu) in human survivors was performed. An enzyme-linked immunosorbent assay specific for full-length recombinant viral proteins NP, VP30, VP40, and GP1-649 (GP lacking the transmembrane domain) of Sudan ebolavirus (Gulu) was used as well as a plaque reduction neutralization test. Serum samples from human survivors, which were collected up to 10 years following recovery, were screened and analyzed. Results demonstrate that samples obtained 10 years following infection contain virus-specific antibodies that can neutralize virus. Neutralization correlates well with immunoreactivity against the viral proteins NP, VP30, and GP1-649. Sera from individuals who died or those with no documented infection but immunoreactive to ebolavirus did not neutralize. This work provides insight into the duration, profile of immunoreactivity, and neutralization capacity of the humoral immune response in ebolavirus survivors.

Citing Articles

High Seroreactivities to Orthoebolaviruses in Rural Cameroon: A Case-Control Study on Nonhuman Primate Bites and a Cross-sectional Survey in Rural Populations.

Ramassamy J, Ayouba A, Thaurignac G, Bilounga Ndongo C, Nnuka P, Betsem E J Infect Dis. 2024; 230(5):e1067-e1076.

PMID: 39126336 PMC: 11565877. DOI: 10.1093/infdis/jiae399.


Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection.

To A, Wong T, Ball A, Lieberman M, Yalley-Ogunro J, Cabus M Vaccine. 2023; 42(3):598-607.

PMID: 38158300 PMC: 10872277. DOI: 10.1016/j.vaccine.2023.12.053.


Bridging Animal and Human Data in Pursuit of Vaccine Licensure.

Finch C, Dowling W, King T, Martinez C, Nguyen B, Roozendaal R Vaccines (Basel). 2022; 10(9).

PMID: 36146462 PMC: 9503666. DOI: 10.3390/vaccines10091384.


Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.

Hargreaves A, Brady C, Mellors J, Tipton T, Carroll M, Longet S Pathogens. 2021; 10(9).

PMID: 34578233 PMC: 8468515. DOI: 10.3390/pathogens10091201.


Development of a multiplex microsphere immunoassay for the detection of antibodies against highly pathogenic viruses in human and animal serum samples.

Surtees R, Stern D, Ahrens K, Kromarek N, Lander A, Kreher P PLoS Negl Trop Dis. 2020; 14(10):e0008699.

PMID: 33095766 PMC: 7641473. DOI: 10.1371/journal.pntd.0008699.